Curcumin exposure induces expression of the Parkinson's disease-associated leucine-rich repeat kinase 2 (LRRK2) in rat mesencephalic cells

Neuroscience Letters

Volumn 468, Issue 2, 2010, Pages 120-124

  Ortiz Ortiz, Miguel A ^a   Morán, José M ^a   Ruiz Mesa, Luz M ^a   Niso Santano, Mireia ^a   Bravo SanPedro, José M ^a   Gómez Sánchez, Rubén ^a   González Polo, Rosa A ^a   Fuentes, José M ^a  

^a CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

Author keywords

Curcumin; LRRK2; Parkin; Parkinson's disease; PINK1; Synuclein

Indexed keywords

ALPHA SYNUCLEIN; CURCUMIN; LEUCINE RICH REPEAT KINASE 2; MESSENGER RNA; PARKIN; PHOSPHOTRANSFERASE; PTEN INDUCED PUTATIVE KINASE 1; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BRAIN NERVE CELL; CELL IMMORTALIZATION; CELL SPECIFICITY; CONTROLLED STUDY; DEGENERATIVE DISEASE; DRUG EXPOSURE; GENE EXPRESSION REGULATION; IMMUNOFLUORESCENCE TEST; MESENCEPHALON; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RAT;

ALPHA-SYNUCLEIN; ANIMALS; CELL LINE; CURCUMIN; MESENCEPHALON; PARKINSON DISEASE; PROTEIN KINASES; PROTEIN-SERINE-THREONINE KINASES; RATS; RNA, MESSENGER; TIME FACTORS; UBIQUITIN-PROTEIN LIGASES;

EID: 70450224433     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2009.10.081     Document Type: Article

References (49)

1. Aggarwal B.B., Kumar A., and Bharti A.C. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res. 23 (2003) 363-398
2. Ammon H.P., and Wahl M.A. Pharmacology of Curcuma longa. Planta Med. 57 (1991) 1-7
3. Anantharam V., Kitazawa M., Wagner J., Kaul S., and Kanthasamy A.G. Caspase-3-dependent proteolytic cleavage of protein kinase Cdelta is essential for oxidative stress-mediated dopaminergic cell death after exposure to methylcyclopentadienyl manganese tricarbonyl. J. Neurosci. 22 (2002) 1738-1751
4. Baum L., Cheung S.K., Mok V.C., Lam L.C., Leung V.P., Hui E., Ng C.C., Chow M., Ho P.C., Lam S., Woo J., Chiu H.F., Goggins W., Zee B., Wong A., Mok H., Cheng W.K., Fong C., Lee J.S., Chan M.H., Szeto S.S., Lui V.W., Tsoh J., Kwok T.C., Chan I.H., and Lam C.W. Curcumin effects on blood lipid profile in a 6-month human study. Pharmacol. Res. 56 (2007) 509-514
5. Biskup S., Moore D.J., Rea A., Lorenz-Deperieux B., Coombes C.E., Dawson V.L., Dawson T.M., and West A.B. Dynamic and redundant regulation of LRRK2 and LRRK1 expression. BMC Neurosci. 8 (2007) 102
6. Bonifati V., Rizzu P., van Baren M.J., Schaap O., Breedveld G.J., Krieger E., Dekker M.C., Squitieri F., Ibanez P., Joosse M., van Dongen J.W., Vanacore N., van Swieten J.C., Brice A., Meco G., van Duijn C.M., Oostra B.A., and Heutink P. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 299 (2003) 256-259
7. Chen J., Tang X.Q., Zhi J.L., Cui Y., Yu H.M., Tang E.H., Sun S.N., Feng J.Q., and Chen P.X. Curcumin protects PC12 cells against 1-methyl-4-phenylpyridinium ion-induced apoptosis by bcl-2-mitochondria-ROS-iNOS pathway. Apoptosis 11 (2006) 943-953
8. Dauer W., and Przedborski S. Parkinson's disease: mechanisms and models. Neuron 39 (2003) 889-909
9. Floris G., Cannas A., Solla P., Murru M.R., Tranquilli S., Corongiu D., Rolesu M., Cuccu S., Sardu C., Marrosu F., and Marrosu M.G. Genetic analysis for five LRRK2 mutations in a Sardinian parkinsonian population: importance of G2019S and R1441C mutations in sporadic Parkinson's disease patients. Parkinsonism Relat. Disord. 15 (2009) 277-280
10. Ganguli M., Chandra V., Kamboh M.I., Johnston J.M., Dodge H.H., Thelma B.K., Juyal R.C., Pandav R., Belle S.H., and DeKosky S.T. Apolipoprotein E polymorphism and Alzheimer disease: the Indo-US Cross-National Dementia Study. Arch. Neurol. 57 (2000) 824-830
11. Gloeckner C.J., Kinkl N., Schumacher A., Braun R.J., O'Neill E., Meitinger T., Kolch W., Prokisch H., and Ueffing M. The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity. Hum. Mol. Genet. 15 (2006) 223-232
12. Gorostidi A., Ruiz-Martinez J., de Munain A.L., Alzualde A., and Masso J.F. LRRK2 G2019S and R1441G mutations associated with Parkinson's disease are common in the Basque Country, but relative prevalence is determined by ethnicity. Neurogenetics 10 (2009) 157-159
13. Han S.S., Keum Y.S., Seo H.J., and Surh Y.J. Curcumin suppresses activation of NF-kappaB and AP-1 induced by phorbol ester in cultured human promyelocytic leukemia cells. J. Biochem. Mol. Biol. 35 (2002) 337-342
14. Han B.S., Iacovitti L., Katano T., Hattori N., Seol W., and Kim K.S. Expression of the LRRK2 gene in the midbrain dopaminergic neurons of the substantia nigra. Neurosci. Lett. 442 (2008) 190-194
15. Higashi S., Biskup S., West A.B., Trinkaus D., Dawson V.L., Faull R.L., Waldvogel H.J., Arai H., Dawson T.M., Moore D.J., and Emson P.C. Localization of Parkinson's disease-associated LRRK2 in normal and pathological human brain. Brain Res. 1155 (2007) 208-219
16. Higashi S., Moore D.J., Yamamoto R., Minegishi M., Sato K., Togo T., Katsuse O., Uchikado H., Furukawa Y., Hino H., Kosaka K., Emson P.C., Wada K., Dawson V.L., Dawson T.M., Arai H., and Iseki E. Abnormal localization of leucine-rich repeat kinase 2 to the endosomal-lysosomal compartment in Lewy body disease. J. Neuropathol. Exp. Neurol. (2009)
17. Hurley M.J., Patel P.H., Jackson M.J., Smith L.A., Rose S., and Jenner P. Striatal leucine-rich repeat kinase 2 mRNA is increased in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned common marmosets (Callithrix jacchus) with L-3, 4-dihydroxyphenylalanine methyl ester-induced dyskinesia. Eur. J. Neurosci. 26 (2007) 171-177
18. Jagatha B., Mythri R.B., Vali S., and Bharath M.M. Curcumin treatment alleviates the effects of glutathione depletion in vitro and in vivo: therapeutic implications for Parkinson's disease explained via in silico studies. Free Radic. Biol. Med. 44 (2008) 907-917
19. Jobin C., Bradham C.A., Russo M.P., Juma B., Narula A.S., Brenner D.A., and Sartor R.B. Curcumin blocks cytokine-mediated NF-kappa B activation and proinflammatory gene expression by inhibiting inhibitory factor I-kappa B kinase activity. J. Immunol. 163 (1999) 3474-3483
20. Kanthasamy A.G., Kitazawa M., Kanthasamy A., and Anantharam V. Dieldrin-induced neurotoxicity: relevance to Parkinson's disease pathogenesis. Neurotoxicology 26 (2005) 701-719
21. Kaul S., Anantharam V., Yang Y., Choi C.J., Kanthasamy A., and Kanthasamy A.G. Tyrosine phosphorylation regulates the proteolytic activation of protein kinase Cdelta in dopaminergic neuronal cells. J. Biol. Chem. 280 (2005) 28721-28730
22. Kaul S., Anantharam V., Kanthasamy A., and Kanthasamy A.G. Wild-type alpha-synuclein interacts with pro-apoptotic proteins PKCdelta and BAD to protect dopaminergic neuronal cells against MPP+-induced apoptotic cell death. Brain Res. Mol. Brain Res. 139 (2005) 137-152
23. Kirkeby S., and Thomsen C.E. Quantitative immunohistochemistry of fluorescence labelled probes using low-cost software. J. Immunol. Methods 301 (2005) 102-113
24. Kitada T., Asakawa S., Hattori N., Matsumine H., Yamamura Y., Minoshima S., Yokochi M., Mizuno Y., and Shimizu N. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392 (1998) 605-608
25. Ma Q.L., Yang F., Rosario E.R., Ubeda O.J., Beech W., Gant D.J., Chen P.P., Hudspeth B., Chen C., Zhao Y., Vinters H.V., Frautschy S.A., and Cole G.M. Beta-amyloid oligomers induce phosphorylation of tau and inactivation of insulin receptor substrate via c-Jun N-terminal kinase signaling: suppression by omega-3 fatty acids and curcumin. J. Neurosci. 29 (2009) 9078-9089
26. Mata I.F., Wedemeyer W.J., Farrer M.J., Taylor J.P., and Gallo K.A. LRRK2 in Parkinson's disease: protein domains and functional insights. Trends Neurosci. 29 (2006) 286-293
27. Miklossy J., Arai T., Guo J.P., Klegeris A., Yu S., McGeer E.G., and McGeer P.L. LRRK2 expression in normal and pathologic human brain and in human cell lines. J. Neuropathol. Exp. Neurol. 65 (2006) 953-963
28. Milosevic J., Schwarz S.C., Ogunlade V., Meyer A.K., Storch A., and Schwarz J. Emerging role of LRRK2 in human neural progenitor cell cycle progression, survival and differentiation. Mol. Neurodegener. 4 (2009) 25
29. Mochizuki H. Parkin gene therapy. Parkinsonism Relat Disord. 15 Suppl. 1 (2009) S43-S45
30. Mythri R.B., Jagatha B., Pradhan N., Andersen J., and Bharath M.M. Mitochondrial complex I inhibition in Parkinson's disease: how can curcumin protect mitochondria?. Antioxid. Redox. Signal. 9 (2007) 399-408
31. Ortiz-Ortiz M.A., Moran J.M., Bravosanpedro J.M., Gonzalez-Polo R.A., Niso-Santano M., Anantharam V., Kanthasamy A.G., Soler G., and Fuentes J.M. Curcumin enhances paraquat-induced apoptosis of N27 mesencephalic cells via the generation of reactive oxygen species. Neurotoxicology (2009) 10.1016/j.neuro.2009.07.016
32. Ortiz-Ortiz M.A., Moran J.M., Gonzalez-Polo R.A., Niso-Santano M., Soler G., Bravo-San Pedro J.M., and Fuentes J.M. Nitric oxide-mediated toxicity in paraquat-exposed SH-SY5Y cells: a protective role of 7-nitroindazole. Neurotoxicol. Res. 16 (2009) 160-173
33. Paisan-Ruiz C., Jain S., Evans E.W., Gilks W.P., Simon J., van der Brug M., Lopez de M.A., Aparicio S., Gil A.M., Khan N., Johnson J., Martinez J.R., Nicholl D., Carrera I.M., Pena A.S., de S.R., Lees A., Marti-Masso J.F., Perez-Tur J., Wood N.W., and Singleton A.B. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 44 (2004) 595-600
34. Polymeropoulos M.H., Lavedan C., Leroy E., Ide S.E., Dehejia A., Dutra A., Pike B., Root H., Rubenstein J., Boyer R., Stenroos E.S., Chandrasekharappa S., Athanassiadou A., Papapetropoulos T., Johnson W.G., Lazzarini A.M., Duvoisin R.C., Di I.G., Golbe L.I., and Nussbaum R.L. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276 (1997) 2045-2047
35. Prasad K.N., Clarkson E.D., La Rosa F.G., Edwards-Prasad J., and Freed C.R. Efficacy of grafted immortalized dopamine neurons in an animal model of parkinsonism: a review. Mol. Genet. Metab. 65 (1998) 1-9
36. Qin X.Y., Cheng Y., Cui J., Zhang Y., and Yu L.C. Potential protection of curcumin against amyloid beta-induced toxicity on cultured rat prefrontal cortical neurons. Neurosci. Lett. 463 (2009) 158-161
37. Qing H., Wong W., McGeer E.G., and McGeer P.L. Lrrk2 phosphorylates alpha synuclein at serine 129: Parkinson disease implications. Biochem. Biophys. Res. Commun. 387 (2009) 149-152
38. Rajeswari A., and Sabesan M. Inhibition of monoamine oxidase-B by the polyphenolic compound, curcumin and its metabolite tetrahydrocurcumin, in a model of Parkinson's disease induced by MPTP neurodegeneration in mice. Inflammopharmacology 16 (2008) 96-99
39. Ramachandran C., Rodriguez S., Ramachandran R., Raveendran Nair P.K., Fonseca H., Khatib Z., Escalon E., and Melnick S.J. Expression profiles of apoptotic genes induced by curcumin in human breast cancer and mammary epithelial cell lines. Anticancer Res. 25 (2005) 3293-3302
40. Samii A., Nutt J.G., and Ransom B.R. Parkinson's disease. Lancet 363 (2004) 1783-1793
41. Skommer J., Wlodkowic D., and Pelkonen J. Gene-expression profiling during curcumin-induced apoptosis reveals downregulation of CXCR4. Exp. Hematol. 35 (2007) 84-95
42. Thomas P., Wang Y.J., Zhong J.H., Kosaraju S., O'Callaghan N.J., Zhou X.F., and Fenech M. Grape seed polyphenols and curcumin reduce genomic instability events in a transgenic mouse model for Alzheimer's disease. Mutat. Res. 661 (2009) 25-34
43. Valente E.M., Abou-Sleiman P.M., Caputo V., Muqit M.M., Harvey K., Gispert S., Ali Z., Del T.D., Bentivoglio A.R., Healy D.G., Albanese A., Nussbaum R., Gonzalez-Maldonado R., Deller T., Salvi S., Cortelli P., Gilks W.P., Latchman D.S., Harvey R.J., Dallapiccola B., Auburger G., and Wood N.W. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 304 (2004) 1158-1160
44. Venderova K., Kabbach G., Abdel-Messih E., Zhang Y., Parks R.J., Imai Y., Gehrke S., Ngsee J., Lavoie M.J., Slack R., Rao Y., Zhang Z., Lu B., Haque M.E., and Park D.S. Leucine-rich repeat kinase interacts with Parkin, DJ-1 and PINK-1 in a Drosophila melanogaster model of Parkinson's disease. Hum. Mol. Genet. (2009)
45. West A.B., Moore D.J., Biskup S., Bugayenko A., Smith W.W., Ross C.A., Dawson V.L., and Dawson T.M. Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 16842-16847
46. Westerlund M., Belin A.C., Anvret A., Bickford P., Olson L., and Galter D. Developmental regulation of leucine-rich repeat kinase 1 and 2 expression in the brain and other rodent and human organs: implications for Parkinson's disease. Neuroscience 152 (2008) 429-436
47. Westerlund M., Ran C., Borgkvist A., Sterky F.H., Lindqvist E., Lundstromer K., Pernold K., Brene S., Kallunki P., Fisone G., Olson L., and Galter D. Lrrk2 and alpha-synuclein are co-regulated in rodent striatum. Mol. Cell Neurosci. 39 (2008) 586-591
48. Woo M.S., Jung S.H., Kim S.Y., Hyun J.W., Ko K.H., Kim W.K., and Kim H.S. Curcumin suppresses phorbol ester-induced matrix metalloproteinase-9 expression by inhibiting the PKC to MAPK signaling pathways in human astroglioma cells. Biochem. Biophys. Res. Commun. 335 (2005) 1017-1025
49. Zbarsky V., Datla K.P., Parkar S., Rai D.K., Aruoma O.I., and Dexter D.T. Neuroprotective properties of the natural phenolic antioxidants curcumin and naringenin but not quercetin and fisetin in a 6-OHDA model of Parkinson's disease. Free Radic. Res. 39 (2005) 1119-1125